Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
Dispelling common misconceptions about the disease and advancing the development of more tolerable topical and oral therapies can offer hope for improved patient outcomes.
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
There are many new devices available to target the aftereffects of acne, allowing dermatologists to tailor treatment plans for the best possible patient outcomes.
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your clinical understanding of fibrotic remodeling and the mechanisms underlying persistent itch and chronic disease activity in prurigo nodularis.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...